A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
收藏DataCite Commons2025-02-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007903/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the long-term safety of SPD489 administered as a
daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with
Attention-deficit/Hyperactivity Disorder (ADHD).
提供机构：
Vivli
创建时间：
2022-06-14
